DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)

Abstract

Currently, many human infectious diseases do not developed effective methods of treatment and prevention. One of the latest successes of biotechnology is the use of adenoviral vectors carrying immunodominant antigens of various pathogens as genetically engineered vaccines both preventive and therapeutic. The use of genetic engineering technologies allows not to use in the manufacture of vaccines live viruses and bacteria, reduces the time needed for vaccine creation and production of new vaccines. Adenoviral vectors naturally penetrate into human cells, causing a rather long and significant both humoral and cellular immune response. In the second part of review, we provide information about the ongoing worldwide clinical trials of adenoviral vector-based vaccines against various infectious diseases such as influenza, malaria, Ebola haemorrhagic fever, tuberculosis, hepatitis and several others, like as to consider selection parameters of volunteers, vaccination schedule, doses of drug administration, results of completed experiments, and preliminary data on currently ongoing research.

Keywords

• adenoviral vector
• vaccine
• clinical trials
• infectious diseases
• human adenovirus
• chimpanzee adenovirus